
GMDA
Healthcare · Biotechnology · $4.3M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2024
EPS trend, 90 days to now · 0.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 7, 2024 | Time not confirmed | -0.14 | 0.00 | +100.0% |
| Mar 27, 2024 | Before the open | -0.15 | -0.04 | +73.3% |
| Nov 14, 2023 | Before the open | -0.17 | -0.01 | +94.1% |
| Aug 14, 2023 | Before the open | -0.19 | -0.31 | -63.2% |
| May 15, 2023 | After the close | -0.27 | -0.27 | 0.0% |
| Mar 27, 2023 | Before the open | -0.25 | -0.30 | -20.0% |
| Nov 14, 2022 | Before the open | -0.31 | -0.29 | +6.5% |
| Aug 15, 2022 | Before the open | -0.29 | -0.31 | -6.9% |
| May 10, 2022 | Before the open | -0.34 | -0.34 | 0.0% |
| Mar 15, 2022 | Before the open | -0.40 | -0.52 | -30.0% |
| Nov 15, 2021 | Before the open | -0.48 | -0.33 | +31.3% |
| Aug 11, 2021 | Before the open | -0.40 | -0.36 | +10.0% |
| May 11, 2021 | Before the open | -0.40 |
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an…
| -0.31 |
| +22.5% |
| Mar 9, 2021 | Before the open | -0.34 | -0.68 | -100.0% |
| Nov 10, 2020 | Before the open | -0.31 | -0.30 | +3.2% |
| Aug 11, 2020 | Before the open | -0.30 | -0.37 | -23.3% |
| May 21, 2020 | Before the open | -0.45 | -0.27 | +40.0% |
| Feb 25, 2020 | Before the open | -0.34 | -0.31 | +8.8% |
| Nov 13, 2019 | After the close | -0.36 | -0.30 | +16.7% |
| Aug 6, 2019 | Before the open | -0.45 | 0.23 | +151.1% |
| May 7, 2019 | After the close | -0.37 | -0.62 | -67.6% |
| Feb 25, 2019 | After the close | -0.44 | -0.91 | -106.8% |
| Oct 30, 2018 | After the close | -5.39 | -0.78 | +85.5% |
| Aug 29, 2018 | Time not confirmed | — | -0.88 | — |